The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis

Journal of Urology

Volumn 195, Issue 6, 2016, Pages 1704-1709

  Haas, Christopher R ^a   Barlow, Lamont J ^a   Badalato, Gina M ^a   Decastro, G Joel ^a   Benson, Mitchell C ^a   McKiernan, James M ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

BCG vaccine; cystectomy; mortality; treatment failure; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; GAMMA INTERFERON; ALPHA INTERFERON; IMMUNOLOGICAL ADJUVANT;

AGED; ARTICLE; BCG VACCINATION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTECTOMY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE URETHRA; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL TIME; THERAPY DELAY; TREATMENT OUTCOME; BLADDER; BLADDER TUMOR; DISEASE EXACERBATION; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; MYCOBACTERIUM BOVIS; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TIME FACTOR; TREATMENT FAILURE; TUMOR INVASION; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; ANTINEOPLASTIC AGENTS; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYCOBACTERIUM BOVIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84975247372     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.01.087     Document Type: Article

References (18)

1. M. Babjuk, M. Burger, R. Zigeuner, and et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639
2. M.C. Hall, S.S. Chang, G. Dalbagni, and et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
3. A.M. Kamat, A. Witjes, M. Brausi, and et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer J Urol 192 2014 305
4. C.L. Amling, J.B. Thrasher, H.A. Frazier, and et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder J Urol 151 1994 31
5. D.R. Yates, M.A. Brausi, J.W. Catto, and et al. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer Eur Urol 62 2012 1088
6. J. Fernandez-Gomez, R. Madero, E. Solsona, and et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 2011 423
7. M. Brausi, J.A. Witjes, D. Lamm, and et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group J Urol 186 2011 2158
8. S. van den Bosch, and J.A. Witjes Long-Term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review Eur Urol 60 2011 493
9. W.J. Catalona, M.A. Hudson, D.P. Gillen, and et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer J Urol 137 1987 220
10. B. Schrier, M.P. Hollander, B.W.G. van Rhijn, and et al. prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy Eur Urol 45 2004 292
11. R.E. Hautmann, B.G. Volkmer, and K. Gust Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3) World J Urol 27 2009 347
12. G.V. Raj, H. Herr, A.M. Serio, and et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer J Urol 177 2007 1283
13. P. Gontero, R. Sylvester, F. Pisano, and et al. Prognostic factors and risk groups in t1g3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients Eur Urol 67 2015 74
14. S. Denzinger, H.M. Fritsche, W. Otto, and et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 53 2008 146
15. J. Fernandez-Gomez, E. Solsona, M. Unda, and et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992
16. F.N. Joudi, B.J. Smith, M.A. O'Donnell, and et al. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy J Urol 175 2006 1634
17. J. Palou, R.J. Sylvester, O. Rodríguez Faba, and et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin Eur Urol 62 2012 118
18. M.J. Resnick, M. Bergey, L. Magerfleisch, and et al. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens BJU Int 107 2011 46